Influence of previous Zika virus infection on acute dengue episode.

Humans Zika Virus Infection Dengue Dengue Virus Antibodies, Viral Zika Virus Cross Reactions

Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 17 05 2023
accepted: 05 10 2023
revised: 21 11 2023
medline: 22 11 2023
pubmed: 9 11 2023
entrez: 9 11 2023
Statut: epublish

Résumé

The co-circulation of flaviviruses in tropical regions has led to the hypothesis that immunity generated by a previous dengue infection could promote severe disease outcomes in subsequent infections by heterologous serotypes. This study investigated the influence of antibodies generated by previous Zika infection on the clinical outcomes of dengue infection. We enrolled 1,043 laboratory confirmed dengue patients and investigated their prior infection to Zika or dengue. Severe forms of dengue disease were more frequent in patients with previous Zika infection, but not in those previously exposed to dengue. Our findings suggest that previous Zika infection may represent a risk factor for subsequent severe dengue disease, but we did not find evidence of antibody-dependent enhancement (higher viral titer or pro-inflammatory cytokine overexpression) contributing to exacerbation of the subsequent dengue infection.

Sections du résumé

BACKGROUND BACKGROUND
The co-circulation of flaviviruses in tropical regions has led to the hypothesis that immunity generated by a previous dengue infection could promote severe disease outcomes in subsequent infections by heterologous serotypes. This study investigated the influence of antibodies generated by previous Zika infection on the clinical outcomes of dengue infection.
METHODOLOGY/PRINCIPAL FINDINGS RESULTS
We enrolled 1,043 laboratory confirmed dengue patients and investigated their prior infection to Zika or dengue. Severe forms of dengue disease were more frequent in patients with previous Zika infection, but not in those previously exposed to dengue.
CONCLUSIONS/SIGNIFICANCE CONCLUSIONS
Our findings suggest that previous Zika infection may represent a risk factor for subsequent severe dengue disease, but we did not find evidence of antibody-dependent enhancement (higher viral titer or pro-inflammatory cytokine overexpression) contributing to exacerbation of the subsequent dengue infection.

Identifiants

DOI: 10.1371/journal.pntd.0011710 PMID: 37943879 PMC: PMC10662752
pubmed: 37943879
doi: 10.1371/journal.pntd.0011710
pii: PNTD-D-23-00592
pmc: PMC10662752
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0011710

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI151807
Pays : United States

Informations de copyright

Copyright: © 2023 Estofolete et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Infect Dis. 1973 Jul;128(1):15-22
pubmed: 4198024
Sci Rep. 2017 Sep 5;7(1):10498
pubmed: 28874759
J Infect Dis. 2018 Jul 13;218(4):536-545
pubmed: 29618091
J Med Virol. 2017 Aug;89(8):1477-1479
pubmed: 28229481
Trends Microbiol. 2018 Mar;26(3):186-190
pubmed: 29122447
BMC Infect Dis. 2019 May 20;19(1):441
pubmed: 31109295
Nat Commun. 2019 Sep 20;10(1):4316
pubmed: 31541110
J Clin Microbiol. 2005 Oct;43(10):4977-83
pubmed: 16207951
Clin Vaccine Immunol. 2010 Dec;17(12):1829-35
pubmed: 20876821
Yale J Biol Med. 1970 Apr;42(5):311-28
pubmed: 5419206
Clin Infect Dis. 2017 Oct 15;65(8):1260-1265
pubmed: 29017246
Lancet Infect Dis. 2021 Jul;21(7):1014-1026
pubmed: 33640077
Emerg Microbes Infect. 2018 Dec 1;7(1):198
pubmed: 30504926
Ann Lab Med. 2019 Nov;39(6):566-571
pubmed: 31240885
J Glob Infect Dis. 2009 Jan;1(1):38-44
pubmed: 20300385
Viruses. 2020 Aug 29;12(9):
pubmed: 32872425
J Gen Virol. 1989 Jan;70 ( Pt 1):37-43
pubmed: 2543738
Trop Parasitol. 2016 Jul-Dec;6(2):113-122
pubmed: 27722099
J Virol. 2011 Feb;85(4):1671-83
pubmed: 21123382
PLoS Pathog. 2017 Aug 3;13(8):e1006487
pubmed: 28771605
Lancet Glob Health. 2018 Feb;6(2):e140-e141
pubmed: 29389533
PLoS Negl Trop Dis. 2020 Jun 24;14(6):e0008203
pubmed: 32579555
Eur J Immunol. 2013 Jun;43(6):1529-44
pubmed: 23505056
Int J Infect Dis. 2020 Dec;101:90-97
pubmed: 32992011
Nat Immunol. 2016 Sep;17(9):1102-8
pubmed: 27339099
Front Cell Infect Microbiol. 2020 Oct 02;10:580096
pubmed: 33123500
JCI Insight. 2020 Feb 13;5(3):
pubmed: 31910161
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7852-7
pubmed: 27354515
Braz J Microbiol. 2016 Dec;47 Suppl 1:38-50
pubmed: 27818091
PLoS One. 2018 Jul 25;13(7):e0200478
pubmed: 30044839
Viruses. 2020 Dec 13;12(12):
pubmed: 33322218
Diagnostics (Basel). 2020 May 14;10(5):
pubmed: 32423058
PLoS One. 2021 Jan 26;16(1):e0244601
pubmed: 33497414
Adv Virus Res. 2003;59:141-75
pubmed: 14696329
Sci Rep. 2020 Jul 9;10(1):11302
pubmed: 32647259
J Infect Dis. 2019 Jan 7;219(2):223-233
pubmed: 30085051
PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2520
pubmed: 24386496
iScience. 2022 Jul 16;25(8):104764
pubmed: 35982798
Nat Commun. 2017 Jun 23;8:15674
pubmed: 28643775
Nat Rev Immunol. 2011 Jul 15;11(8):532-43
pubmed: 21760609
J Immunol. 2014 Aug 15;193(4):1864-72
pubmed: 25015827
Rev Bras Epidemiol. 2021 Apr 02;24:e210020
pubmed: 33825776
BMC Infect Dis. 2021 Aug 4;21(1):749
pubmed: 34348665
PLoS Negl Trop Dis. 2011 Sep;5(9):e1309
pubmed: 21909448
Emerg Infect Dis. 2007 Jan;13(1):176-8
pubmed: 17370543
Cytokine. 2013 Nov;64(2):477-85
pubmed: 24011563
J Infect Public Health. 2019 Mar - Apr;12(2):178-181
pubmed: 30301701
Microbiol Spectr. 2014 Dec;2(6):
pubmed: 26104444
J Clin Virol. 2017 Nov;96:20-25
pubmed: 28918127
Nat Rev Rheumatol. 2018 Aug;14(8):453-466
pubmed: 30006601
Nat Commun. 2019 Mar 29;10(1):1408
pubmed: 30926818
J Virol. 2007 Feb;81(4):1592-600
pubmed: 17151115
Nat Rev Immunol. 2015 Dec;15(12):745-59
pubmed: 26603900
J Infect Dis. 2017 Mar 1;215(5):781-785
pubmed: 28039355
Science. 2016 Aug 19;353(6301):823-6
pubmed: 27417494
Trans R Soc Trop Med Hyg. 2008 Jun;102(6):522-3
pubmed: 18420239
J Clin Invest. 2004 Apr;113(7):946-51
pubmed: 15057297
J Clin Virol. 2007 Sep;40(1):84-6
pubmed: 17658293
Nat Med. 2018 Jun;24(6):721-723
pubmed: 29867228
Science. 2017 Apr 14;356(6334):175-180
pubmed: 28360135
mBio. 2016 Jul 19;7(4):
pubmed: 27435464
Immunity. 2019 Mar 19;50(3):751-762.e5
pubmed: 30737148
J Gen Virol. 2017 Jul;98(7):1702-1712
pubmed: 28691657
EMBO Rep. 2018 Feb;19(2):206-224
pubmed: 29282215
Cell Host Microbe. 2018 Nov 14;24(5):743-750.e5
pubmed: 30439343
Viruses. 2019 Nov 19;11(11):
pubmed: 31752352
Science. 2020 Aug 28;369(6507):1123-1128
pubmed: 32855339
J Gen Virol. 2007 Feb;88(Pt 2):365-375
pubmed: 17251552
Clin Rev Allergy Immunol. 2018 Dec;55(3):379-390
pubmed: 30109481

Auteurs

Cassia F Estofolete (CF)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Alice F Versiani (AF)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.
Department of Pathology, University of Texas Medical Branch; Galveston, Texas, United States of America.

Fernanda S Dourado (FS)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Bruno H G A Milhim (BHGA)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Carolina C Pacca (CC)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Gislaine C D Silva (GCD)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Nathalia Zini (N)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Barbara F Dos Santos (BFD)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Flora A Gandolfi (FA)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Natalia F B Mistrão (NFB)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Pedro H C Garcia (PHC)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Rodrigo S Rocha (RS)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.

Lee Gehrke (L)

Institute for Medical Engineering and Science, Massachusetts Institute of Technology; Cambridge, Massachusetts, United States of America.
Department of Microbiology, Harvard Medical School; Boston, Massachusetts, United States of America.

Irene Bosch (I)

Institute for Medical Engineering and Science, Massachusetts Institute of Technology; Cambridge, Massachusetts, United States of America.

Rafael E Marques (RE)

Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM); Campinas, Sao Paulo, Brazil.

Mauro M Teixeira (MM)

Department of Biochemistry and Immunology, Universidade Federal de Minas Gerais; Belo Horizonte, Minas Gerais, Brazil.

Flavio G da Fonseca (FG)

Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais; Belo Horizonte, Minas Gerais, Brazil.
Centro de Tecnoogia em Vacinas da UFMG, Universidade Federal de Minas Gerais; Belo Horizonte, Minas Gerais, Brazil.

Nikos Vasilakis (N)

Department of Pathology, University of Texas Medical Branch; Galveston, Texas, United States of America.
Center for Vector-Borne and Zoonotic Diseases, University of Texas Medical Branch; Galveston, Texas, United States of America.
Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch; Galveston, Texas, United States of America.
Center for Tropical Diseases, University of Texas Medical Branch; Galveston, Texas, United States of America.
Institute for Human Infection and Immunity, University of Texas Medical Branch; Galveston, Texas, United States of America.

Maurício L Nogueira (ML)

Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP); São José do Rio Preto, Sao Paulo, Brazil.
Department of Pathology, University of Texas Medical Branch; Galveston, Texas, United States of America.
ORCID: 0000-0003-1102-2419

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Influence of previous Zika virus infection on...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Flaviviridae › Infections à flavivirus › Infection par le virus Zika › Influence of previous Zika virus infection on...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Fièvres hémorragiques virales › Dengue › Influence of previous Zika virus infection on...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Flaviviridae › Flavivirus › Virus de la dengue › Influence of previous Zika virus infection on...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Influence of previous Zika virus infection on...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Flaviviridae › Flavivirus › Virus Zika › Influence of previous Zika virus infection on...
questionsmedicales.fr › Phénomènes du système immunitaire › Réaction antigène-anticorps › Réactions croisées › Influence of previous Zika virus infection on...